User:I enjoy sandwiches/cerebrolysin

From Wikipedia, the free encyclopedia
Vial of the product.

Cerebrolysin (developmental code name FPF-1070) is a mixture of peptides derived from pig brains that can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).

Little is known about the clinical efficacy of cerebrolysin. Cochrane reviews suggest that it does not have benefit in the treatment of acute stroke,[1][2] though some benefit has been seen with vascular dementia;[2][3] further high quality research is needed to confirm these early reviews. Early meta analyses have suggested potential benefit with traumatic brain injury[4][5] It is also being clinically studied with a wide variety of neurodegenerative disorders, though research is preliminary.[6][7][8][9][10]

Medical uses[edit]

Stroke[edit]

Early Cochrane reviews suggest that there is no benefit for treatment of acute ischemic stroke with cerebrolysin, though they also emphasize the need for further high quality studies.Cite error: The opening <ref> tag is malformed or has a bad name (see the help page).Cite error: The opening <ref> tag is malformed or has a bad name (see the help page). Similar studies of ischemic stroke in Asian subpopulations found an absence of benefit as well.[11]

An early study suggested a lack of benefit with a specific kind of hemorrhagic stroke.[12]

Dementia[edit]

Reviews suggest an improvement in cognitive function with cerebrolysin use for vascular dementia, though as with studies on stroke, further high quality research is needed.<ref="pmid23440834"/><ref="pmid28430363"/>

Adverse effects[edit]

In trials studying the use of cerebrolysin after acute stroke, it was associated with an increased risk of "serious adverse events". These were specifically defined as:

"any untoward medical occurrence that, at any dose, resulted in death, [was] life‐threatening, required inpatient hospitalisation or resulted in prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, [was] a congenital anomaly/birth defect, or [was] a medically important event or reaction”.Cite error: The opening <ref> tag is malformed or has a bad name (see the help page).Cite error: The opening <ref> tag is malformed or has a bad name (see the help page).

Mechanism of action[edit]

In vitro and animal studies suggest neurotrophic effects of cerebrolysin similar to endogenous neurotrophic factors, though its specific molecular pharmacodynamics are not clear.[13] Studies of dementia suggest decreased beta-amyloid deposition.[14]

History[edit]

The preparation was allegedly first created in 1949 by Gerhart Harrer, an Austrian professor at the University of Innsbruck.[citation needed]

Cerebrolysin is widely used in Russia, Eastern Europe, China, and other post-Soviet and Asian countries.[15] It has been included on the list of Vital and Essential Medicines (ЖНВЛС) in Russia since 1992.[16]

While it was listed as one reason that one pharmacy was prosecuted for illegal distribution, it is not a scheduled drug in the United States.[17][18]

Research[edit]

Early studies have suggested benefit when administered following traumatic brain injury.[19][20] It is also being studied with cerebral palsy, multiple sclerosis and for treatment of negative symptoms of schizophrenia such as catatonia, though research is very preliminary.

Very early studies have suggested a role in the treatment of cervical myelopathy.[citation needed]

References[edit]

  1. ^ Ziganshina, LE; Abakumova, T; Hoyle, CH (14 July 2020). "Cerebrolysin for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 7 (9): CD007026. doi:10.1002/14651858.CD007026.pub6. PMID 32662068. S2CID 220519368.
  2. ^ a b Ziganshina, LE; Abakumova, T; Vernay, L (21 April 2017). "Cerebrolysin for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 4: CD007026. doi:10.1002/14651858.CD007026.pub5. PMID 28430363. Cite error: The named reference "pmid28430363" was defined multiple times with different content (see the help page).
  3. ^ Chen, N; Yang, M; Guo, J; Zhou, M; Zhu, C; He, L (31 January 2013). "Cerebrolysin for vascular dementia". The Cochrane Database of Systematic Reviews (1): CD008900. doi:10.1002/14651858.CD008900.pub2. PMID 23440834.
  4. ^ Ghaffarpasand, F; Torabi, S; Rasti, A; Niakan, MH; Aghabaklou, S; Pakzad, F; Beheshtian, MS; Tabrizi, R (2019). "Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis". Neuropsychiatric Disease and Treatment. 15: 127–135. doi:10.2147/NDT.S186865. PMID 30643411. S2CID 58010056.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  5. ^ El Sayed, I; Zaki, A; Fayed, AM; Shehata, GM; Abdelmonem, S (April 2018). "A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury". Neurosurgical Review. 41 (2): 427–438. doi:10.1007/s10143-016-0775-y. PMID 27539610. S2CID 3980956.
  6. ^ Xiao, S; Xue, H; Li, G; Yuan, C; Li, X; Chen, C; Wu, HZ; Mitchell, P; Zhang, M (February 2012). "Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms". The Australian and New Zealand Journal of Psychiatry. 46 (2): 153–60. doi:10.1177/0004867411433213. PMID 22311531. S2CID 206397952.
  7. ^ Khabirov, FA; Khaybullin, TI; Granatov, EV; Shakirzianova, SR (2016). "[Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 116 (12): 48–53. doi:10.17116/jnevro201611612148-53. PMID 28139626.
  8. ^ Nasiri, J; Safavifar, F (June 2017). "Effect of cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial". Acta Neurologica Belgica. 117 (2): 501–505. doi:10.1007/s13760-016-0743-x. PMID 28074392. S2CID 3805375.
  9. ^ Windisch M, Gschanes A, Hutter-Paier B (1998). "Neurotrophic activities and therapeutic experience with a brain derived peptide preparation". J. Neural Transm. Suppl. Journal of Neural Transmission. Supplementa. 53: 289–98. doi:10.1007/978-3-7091-6467-9_25. ISBN 978-3-211-83114-4. PMID 9700665.
  10. ^ Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS (2012). "Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals". CNS Neurol Disord Drug Targets. 11 (1): 40–9. doi:10.2174/187152712799960781. PMID 22229324.
  11. ^ Heiss, WD; Brainin, M; Bornstein, NM; Tuomilehto, J; Hong, Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA), Investigators. (March 2012). "Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial". Stroke. 43 (3): 630–6. doi:10.1161/STROKEAHA.111.628537. PMID 22282884. S2CID 26004422.
  12. ^ Woo, PYM; Ho, JWK; Ko, NMW; Li, RPT; Jian, L; Chu, ACH; Kwan, MCL; Chan, Y; Wong, AKS; Wong, HT; Chan, KY; Kwok, JCK (3 November 2020). "Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage". BMC Neurology. 20 (1): 401. doi:10.1186/s12883-020-01908-9. PMID 33143640. S2CID 226231630.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  13. ^ Plosker, GL; Gauthier, S (2009). "Cerebrolysin: a review of its use in dementia". Drugs & Aging. 26 (11): 893–915. doi:10.2165/11203320-000000000-00000. PMID 19848437.
  14. ^ Masliah E, Díez-Tejedor E (2012). "The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders". Drugs Today. 48 Suppl A: 3–24. doi:10.1358/dot.2012.48(Suppl.A).1739716 (inactive 2023-01-01). PMID 22514792.{{cite journal}}: CS1 maint: DOI inactive as of January 2023 (link)
  15. ^ Cite error: The named reference :1 was invoked but never defined (see the help page).
  16. ^ распоряжением Правительства РФ от 7 декабря 2011 года № 2199-р
  17. ^ Rogers, Steve (29 October 2020). "Nicholasville compounding pharmacy, owner plead guilty to distribution". ABC 36 News.
  18. ^ "Nicholasville Compounding Pharmacy and Its Owner Sentenced for Unlawful Distribution of Prescription Drugs Unlawful Distribution of Prescription Drugs". www.justice.gov. 24 February 2021.
  19. ^ Ghaffarpasand, F; Torabi, S; Rasti, A; Niakan, MH; Aghabaklou, S; Pakzad, F; Beheshtian, MS; Tabrizi, R (2019). "Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis". Neuropsychiatric Disease and Treatment. 15: 127–135. doi:10.2147/NDT.S186865. PMID 30643411. S2CID 58010056.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  20. ^ El Sayed, I; Zaki, A; Fayed, AM; Shehata, GM; Abdelmonem, S (April 2018). "A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury". Neurosurgical Review. 41 (2): 427–438. doi:10.1007/s10143-016-0775-y. PMID 27539610. S2CID 3980956.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:I_enjoy_sandwiches/cerebrolysin&oldid=1130946071"